Clinical Trials

Polycythemia Vera

NCT06186856 2026-04-22

DATAMAST

13,000 enrolled

Mast Cell Activation Disorders, Mastocytosis

NCT06303193 2026-04-22

Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

Classical hematologyMyeloid

160 enrolled

Anemia, Aplastic, Anemia, Refractory, with Excess of Blasts, Bone Marrow Diseases, Myelodysplastic Syndromes, Myeloproliferative Disorders

NCT06599762 2026-04-22

MYELO-CAN:TXA

Classical hematologyMyeloidOther hematologic neoplasm

75 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Thrombocytopenia, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases

NCT06904066 2026-04-22

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

86 enrolled

Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07264959 2026-04-22

An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)

150 enrolled

Phase 2 Not yet recruiting

Mastocytosis, Mastocytosis, Systemic

NCT07528417 2026-04-22

MYELO-CAN:ABX

75 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Neutropenia, Leukemia, Myeloid, Acute

NCT00923442 2026-04-21

Biology Studies of Hematologic Cancers

Enrolling by invitation

550 enrolled

CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Hodgkin Disease, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03213678 2026-04-21

Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)

Phase 2 Completed

18 enrolled 12 charts

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT03578367 2026-04-21

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.

Phase 2 Completed

104 enrolled 33 charts

Hematologic Diseases, Leukemia, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05786924 2026-04-21

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

CNSGastrointestinalHead & NeckMyeloidThoracic

554 enrolled

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Histiocytosis

NCT06514534 2026-04-21

ASC4TARGET

20 enrolled

Phase 1 Not yet recruiting

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT07379125 2026-04-21

Therapeutic RSK1 Targeting in Myelofibrosis

18 enrolled

Classical hematologyMyeloid

Anemia, Bone Marrow Diseases, Hematologic Diseases, Myeloproliferative Disorders, Splenomegaly, Bone Marrow Neoplasms, Primary Myelofibrosis

NCT00044122 2026-04-20

Study of Factors Regulating Mast Cell Proliferation

600 enrolled

LymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Mastocytosis

NCT00720785 2026-04-20

Natural Killer Cells and Bortezomib to Treat Cancer

Phase 1 Completed

35 enrolled

Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Neoplasm Metastasis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02211755 2026-04-20

Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors

Phase 1 Completed

28 enrolled

LymphoidMyeloid

Lymphoma, Myelodysplastic Syndromes, Neoplasms

NCT03441113 2026-04-20

Extended Access of Momelotinib in Adults With Myelofibrosis

237 enrolled

Neoplasms, Primary Myelofibrosis

NCT03827343 2026-04-20

Retrospective Study of Immunotherapy Related Toxicities and Factors Impacting Outcomes in Children and Adults With Cancer

Active not recruiting

500 enrolled

Lymphohistiocytosis, Hemophagocytic, Macrophage Activation Syndrome

NCT04910685 2026-04-20

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

Phase 2/3 Recruiting

534 enrolled

Mastocytosis, Systemic

NCT05564390 2026-04-20

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

2,000 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT05943522 2026-04-20

Asciminib RMP Study

600 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05969860 2026-04-20

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

220 enrolled

MyeloidPlasma cell

Multiple Myeloma, Myelodysplastic Syndromes

NCT07143669 2026-04-20

Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations

450 enrolled

Mastocytosis, Leukemia, Myelomonocytic, Chronic, Postural Orthostatic Tachycardia Syndrome

NCT07255638 2026-04-20

A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany

80 enrolled

Phase 2 Not yet recruiting

Mastocytosis, Mastocytosis, Systemic

NCT07538401 2026-04-20

ASCiminib, With or Without Dasatinib Combination, as a 2nd-Line Therapy to ADVANCE the Treatment for Chronic Myelogenous Leukemia in Chronic Phase (ASC2ADVANCE)

45 enrolled

Phase 2/3 Not yet recruiting

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT07539779 2026-04-20

Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis

196 enrolled

Hematologic Neoplasms, Primary Myelofibrosis

NCT05177211 2026-04-17

Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)

25 enrolled 13 charts

Myeloproliferative Disorders, Leukemia, Neutrophilic, Chronic

NCT05554406 2026-04-17

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

335 enrolled

Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT05607199 2026-04-17

BHARAT-1

Phase 1 Terminated

27 enrolled

Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06034002 2026-04-17

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

290 enrolled

Myeloproliferative Disorders, Thrombocythemia, Essential, Primary Myelofibrosis

NCT06427811 2026-04-17

ASC4INDIA

Phase 4 Completed

85 enrolled

Phase 1 Not yet recruiting

Bronchiolitis Obliterans Syndrome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT07302776 2026-04-17

TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT

50 enrolled

Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

NCT00816114 2026-04-16

Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial

3,000 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04140487 2026-04-16

Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

97 enrolled

Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

NCT04493138 2026-04-16

Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations

58 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic

NCT06439199 2026-04-16

CYTOK-AZA

60 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT06817720 2026-04-16

Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

50 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT07493538 2026-04-16

MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases

132 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT07532824 2026-04-16

UHKT-PTC-TMI-1

Classical hematologyMyeloidOther hematologic neoplasm

16 enrolled

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT01384513 2026-04-15

A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies

Phase 2 Completed

40 enrolled 15 charts

Classical hematologyDermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Pdgfra-Associated Chronic Eosinophilic Leukemia, Congenital Abnormalities, Anemia, Aplastic, Anemia, Refractory, Hodgkin Disease, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Mastocytosis, Multiple Myeloma, Mycosis Fungoides, Myeloproliferative Disorders, Polycythemia Vera, Recurrence, Sezary Syndrome, Thrombocythemia, Essential, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Leukemia, Myelomonocytic, Juvenile, Primary Myelofibrosis

NCT02250937 2026-04-15

Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

116 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05886049 2026-04-15

Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene

28 enrolled

Acute Myeloid Leukemia With KMT2A Rearrangement

NCT07166419 2026-04-15

Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia

24 enrolled

Blast Crisis, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07216443 2026-04-15

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

MyeloidOther hematologic neoplasmOther neoplasm

80 enrolled

Acute Disease, Bone Marrow Diseases, Disease, Graft vs Host Disease, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Precancerous Conditions, Preleukemia, Syndrome, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Disease Attributes

NCT07441694 2026-04-15

Study of INCA036978 in Participants With Myeloproliferative Neoplasms

218 enrolled

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT00900198 2026-04-14

Collection of Tissue Samples for Cancer Research

LymphoidMyeloidPlasma cell

5,000 enrolled

Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms

NCT02392572 2026-04-14

ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome

120 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03155620 2026-04-14

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)